Inmune Bio, Inc. Files 8-K: Director & Officer Changes
Ticker: INMB · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $500,000, $275,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Inmune Bio filed an 8-K for director/officer changes and compensation updates.
AI Summary
On November 26, 2025, Inmune Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive officers, as well as updates to compensatory arrangements. The filing also includes financial statements and exhibits, though specific details on the individuals or financial figures are not provided in this excerpt.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — 8-K filings concerning director and officer changes, while routine, can sometimes precede significant strategic shifts or indicate internal issues.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- November 26, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-38793 (identifier) — SEC File Number
- 47-5205835 (identifier) — IRS Employer Identification No.
- 225 NE Mizner Blvd. , Suite 640 , Boca Raton , Florida 33432 (address) — Address of Principal Executive Offices
- 561-710-0512 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made to Inmune Bio, Inc.'s board of directors or executive officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers,' but the specific details of these changes are not provided in the excerpt.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 26, 2025.
Where is Inmune Bio, Inc.'s principal executive office located?
The principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is the SEC file number for Inmune Bio, Inc.?
The SEC file number for Inmune Bio, Inc. is 001-38793.
What is the primary business of Inmune Bio, Inc. according to the filing?
The Standard Industrial Classification indicates the company is in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Stats: 1,238 words · 5 min read · ~4 pages · Grade level 11.6 · Accepted 2025-11-28 13:00:50
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
- $500,000 — Mr. Moss will be paid a base salary of $500,000 per annum and is eligible to receive an
- $275,000 — lspermann will be paid a base salary of $275,000 per annum and is eligible to receive an
Filing Documents
- ea0267546-8k_inmune.htm (8-K) — 46KB
- ea026754601ex10-1_inmune.htm (EX-10.1) — 63KB
- ea026754601ex10-2_inmune.htm (EX-10.2) — 61KB
- ea026754601ex10-3_inmune.htm (EX-10.3) — 88KB
- 0001213900-25-115921.txt ( ) — 480KB
- inmb-20251126.xsd (EX-101.SCH) — 3KB
- inmb-20251126_lab.xml (EX-101.LAB) — 33KB
- inmb-20251126_pre.xml (EX-101.PRE) — 22KB
- ea0267546-8k_inmune_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: November 28, 2025 By: /s/ David Moss David Moss Chief Executive Officer 3